Study identifier:D8450C00005
ClinicalTrials.gov identifier:NCT06194825
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 3, Randomized Study, With Initial 24-week, Double-Blind and Placebo-Controlled Treatment Phase, Followed by An 80-week Open-label Extension Treatment Phase to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-Term Safety in Chinese Participants With Transthyretin Amyloid Cardiomyopathy (EPIC-ATTR)
Transthyretin Amyloid Cardiomyopathy
Phase 3
No
Eplontersen, Placebo
All
64
Interventional
20 Years - 90 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
The purpose of this study is to investigate the effect of eplontersen compared to placebo on the reduction of serum TTR concentration and long-term safety in Chinese participants with hereditary or wild-type transthyretin amyloid cardiomyopathy.
This is a Phase 3, randomized study, with initial 24-week double-blind and placebo-controlled treatment phase, then followed by an open-label extension treatment phase to evaluate the effect of eplontersen on the TTR reduction and long-term safety in Chinese participants with ATTR-CM. Eligible participants will be randomized in a 3:1 ratio to either eplontersen or placebo for a treatment period of 24 weeks. The double-blind treatment phase will be followed by 80-week open label treatment phase (Participants initially assigned to placebo will switch to eplontersen treatment at 24 weeks), to evaluate long term safety and tolerability of eplontersen treatment. This study will be performed in about 30 to 35 study centres in China mainland.
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Eplontersen Eplontersen by subcutaneous injection once every 4 weeks | Drug: Eplontersen Eplontersen by subcutaneous injection |
Placebo Comparator: placebo Eplontersen-matching placebo by subcutaneous injection once every 4 weeks | Drug: Placebo Eplontersen-matching placebo by subcutaneous injection |